Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

221. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. Full Text available with Trip Pro

Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. To examine the effect of a reduced sodium and increased potassium and magnesium intake on blood pressure.Randomised double blind placebo controlled trial.General population of a suburb of Rotterdam.100 men and women between 55 and 75 years of age with untreated mild to moderate hypertension.During 24 weeks the intervention group received a mineral salt (sodium (...) : potassium: magnesium 8:6:1) and foods prepared with the mineral salt. Controls received common salt and foods.Change in blood pressure.Complete follow up was achieved for 97 of the 100 randomised subjects. Systolic blood pressure (mean of measurements at weeks 8, 16, and 24) fell by 7.6 mm Hg (95% confidence interval 4.0 to 11.2) and diastolic blood pressure by 3.3 mm Hg (0.8 to 5.8) in the mineral salt group compared with the controls, with a 28% decrease in urinary sodium excretion and a 22% increase

1994 BMJ Controlled trial quality: predicted high

222. Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. Full Text available with Trip Pro

Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. To investigate the effect of long term oral magnesium treatment on incidence of cardiac events among survivors of an acute myocardial infarction.Double blind, placebo controlled parallel study in which patients were randomised to treatment or placebo.Two coronary care units and corresponding outpatient clinics.468 survivors of an acute myocardial infarction (289 men and 178 women (...) ) aged 31-92.One tablet of 15 mmol magnesium hydroxide or placebo daily for one year.Incidences of reinfarction, sudden death, and coronary artery bypass grafting in one year.There was no significant difference between treatment and placebo groups in the incidence of each of the three cardiac events, but when the events were combined and drop outs were excluded from calculations there was a significantly higher incidence of events in the treatment group (56/167 v 33/153; relative risk 1.55 (95

1993 BMJ Controlled trial quality: predicted high

223. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. (Abstract)

Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. To determine whether magnesium administration is effective in reducing postoperative morbidity and mortality after cardiac surgery.Randomized, double-blind, placebo-controlled trial.A tertiary acute-care 500-bed university teaching hospital.Over a 6-month period, 100 patients electively scheduled for cardiac surgery involving cardiopulmonary bypass were studied.Fifty patients (...) were randomized to receive an intravenous infusion of magnesium chloride, 2 g, and 50 patients received placebo intraoperatively after the termination of cardiopulmonary bypass.Magnesium-treated patients had a significantly decreased frequency (P < .04) of postoperative ventricular dysrhythmias (eight [16%] of 50) compared with placebo-treated patients (17 [34%] of 50). Patients who were normomagnesemic postoperatively had new supraventricular dysrhythmias less frequently (P < .03) than patients

1992 JAMA Controlled trial quality: predicted high

224. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) (Abstract)

Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) The cardiovascular actions of the magnesium ion at pharmacological concentrations include coronary and systemic vasodilatation, platelet inhibition, and antiarrhythmic effects. Magnesium has also been reported to protect myocardial tissue in experimental models of ischaemia and reperfusion. Several small clinical trials in suspected acute (...) myocardial infarction have suggested that early mortality can be reduced by intravenous infusion of magnesium salts in the acute phase, but none has been of sufficient size to be conclusive. We therefore conducted a randomised, double blind, placebo controlled study in 2316 patients with suspected acute myocardial infarction who received either intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h) or physiological saline. The primary outcome measure was 28-day mortality, which

1992 Lancet Controlled trial quality: predicted high

225. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. Full Text available with Trip Pro

Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. To investigate the effect of intravenous magnesium on mortality in suspected acute myocardial infarction.Systematic overview of all available randomised trials in which patients were allocated to receive either intravenous magnesium or otherwise similar treatment without magnesium.Coronary care units of several hospitals.1301 patients in seven randomised trials.Short term (...) mortality.Considering the seven trials collectively there were 25 (3.8%) deaths among 657 patients allocated to receive magnesium and 53 (8.2%) deaths among 644 patients allocated control, generally during hospital follow up. This represents a 55% reduction in the odds of death (p less than 0.001) with 95% confidence intervals ranging from about one third to about two thirds. 70 of 648 patients allocated magnesium compared with 109 of 641 controls had serious ventricular arrhythmias, suggesting that magnesium

1991 BMJ Controlled trial quality: uncertain

226. Red blood cell magnesium and chronic fatigue syndrome. (Abstract)

Red blood cell magnesium and chronic fatigue syndrome. The hypotheses that patients with chronic fatigue syndrome (CFS) have low red blood cell magnesium and that magnesium treatment would improve the wellbeing of such patients were tested in a case-control study and a randomised, double-blind, placebo-controlled trial, respectively. In the case-control study, 20 patients with CFS had lower red cell magnesium concentrations than did 20 healthy control subjects matched for age, sex, and social (...) class (difference 0.1 mmol/l, 95% confidence interval [CI] 0.05 to 0.15). In the clinical trial, 32 patients with CFS were randomly allocated either to intramuscular magnesium sulphate every week for 6 weeks (15 patients) or to placebo (17). Patients treated with magnesium claimed to have improved energy levels, better emotional state, and less pain, as judged by changes in the Nottingham health profile. 12 of the 15 treated patients said that they had benefited from treatment, and in 7 patients

1991 Lancet Controlled trial quality: predicted high

227. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. Full Text available with Trip Pro

Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. To evaluate the antihypertensive activity of potassium given alone or in combination with magnesium in patients with mild hypertension.A double blind, randomised, placebo controlled, crossover trial of 32 weeks' duration.Cardiology outpatient department, Sassoon General Hospitals, Pune, India.37 Adults with mild hypertension (diastolic blood pressure less than 110 mm Hg).Patients (...) received either placebo or potassium 60 mmol/day alone or in combination with magnesium 20 mmol/day in a crossover design. No other drug treatment was allowed.Blood pressure and heart rate assessed at weekly intervals and biochemical parameters at monthly intervals.Potassium alone or in combination with magnesium produced a significant reduction in systolic and diastolic blood pressures (p less than 0.001) and a significant reduction in serum cholesterol concentration (p less than 0.05); other

1990 BMJ Controlled trial quality: uncertain

228. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. (Abstract)

Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. Conventional nebulized beta-agonist therapy has met with disappointing results in an increasing number of moderate to severe asthmatics who may be characterized as "poor responders." Thirty-eight patients suffering from acute exacerbations of moderate to severe asthma were treated in an emergency department with an intravenous infusion of saline placebo or 1.2 g of magnesium sulfate after conventional (...) ). Intravenous magnesium sulfate may represent a beneficial adjunct therapy in patients with moderate to severe asthma who show little improvement with beta-agonists.

1989 JAMA Controlled trial quality: predicted high

229. Intravenous magnesium in acute myocardial infarction. (Abstract)

Intravenous magnesium in acute myocardial infarction. In a double-blind, placebo-controlled study, 273 patients with suspected acute myocardial infarction (AMI) were randomised to receive either magnesium intravenously or placebo immediately on admission to hospital. Of 130 patients with proven AMI 56 received magnesium and 74 received placebo. During the first 4 weeks after treatment mortality was 7% in the magnesium group and 19% in the placebo group. In the magnesium group 21% of patients (...) had arrhythmias that needed treatment, compared with 47% in the placebo group. No adverse effects of intravenous magnesium were observed.

1986 Lancet Controlled trial quality: predicted high

230. Magnesium therapy in neonatal tetany. (Abstract)

Magnesium therapy in neonatal tetany. 104 infants with symptomatic hypocalcaemia were randomly allocated to treatment with calcium gluconate, phenobarbitone, or magnesium sulphate. Infants treated with magnesium sulphate had higher plasma-calcium concentrations after 48 hours' treatment and fewer convulsions during and after the treatment period. Magnesium sulphate is recommended as the treatment of choice in symptomatic neonatal tetany whether or not there is hypomagnesaemia.

1977 Lancet Controlled trial quality: uncertain